

THE CLAIMS CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. The anhydrous crystalline form of (1,1-dioxo-hexahydro-1 λ 6*-thiopyran-4-yl)-{(S)-3-[1-(6-methoxy-5-methyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-methanone.
2. The anhydrous crystalline form according to claim 1, characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta +/- 0.2 degrees: 9.1, 10.2, 11.9, 13.0, 17.1, 17.7, 18.7, 20.3, 20.8, 26.0, 26.7, 23.2, 24.1, 24.8, 29.3, 27.4, and 21.4.
3. The anhydrous crystalline form according to claim 1 having an X-ray diffraction spectrum substantially the same as the X-ray powder diffraction spectrum shown in Figure 1.
4. The anhydrous crystalline form according to claim 1 having a differential scanning calorimetry graph substantially the same as that shown in shown in Figure 2.
5. ~~A~~The form according to any_one of claims 1 to 4, for use as pharmaceutical.
6. A combination comprising a therapeutically effective amount of a form according to any_one of claims 1 to 4, and one or more therapeutically active agents.
7. Use of a form according to any_one of claims 1 to 4, for the manufacture of a medicament for the treatment of a-diseases or disorders which are mediated by the activity of the PI3K enzymes, ~~preferably by the activity of the PI3K δ isoform.~~

8. A form according to any one of claims 1 to 4, for use in the treatment of a diseases or disorders which are mediated by the activity of the PI3K enzymes, preferably by the activity of the PI3K δ isoform.
9. The form according to claim 8, for use in the treatment of diseases or disorders which are mediated by the activity of the PI3K δ isoform.
910. A pharmaceutical composition comprising a therapeutically effective amount of a form according to any one of claims 1 to 4, and one or more pharmaceutically acceptable carriers.
- ~~10. A method of modulating the activity of the PI3K enzymes, preferably of the PI3K δ isoform, in a subject, comprising the step of administering to a subject a therapeutically effective amount of a form according to anyone of claims 1 to 4.~~
- ~~11. Use of a form according to anyone of claims 1 to 4, for the treatment of a disorder or a disease in a subject mediated by the activity of the PI3K enzymes, preferably by the activity of the PI3K δ isoform~~
11. Use according to claim 7, wherein the PI3K enzyme is the PI3K δ isoform.